New perspectives on the design of cytokines and growth factors

Trends in Biotechnology

Volumn 18, Issue 11, 2000, Pages 455-461

  Kallen, Karl Josef ^a   Grötzinger, Joachim ^b   Rose John, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; CYTOKINE; EPITOPE; ERYTHROPOIETIN; GROWTH FACTOR; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; HYBRID PROTEIN; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; THROMBOPOIETIN;

DIMERIZATION; DNA RECOMBINATION; DRUG DESIGN; DRUG SYNTHESIS; LIGAND BINDING; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; TECHNIQUE;

ANIMAL; BIOTECHNOLOGY; COMBINATORIAL CHEMISTRY TECHNIQUES; CYTOKINES; DRUG DESIGN; EPITOPES; GROWTH SUBSTANCES; HUMAN; LIGANDS; MODELS, MOLECULAR; RECEPTORS, CYTOKINE; RECEPTORS, GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SUPPORT, NON-U.S. GOV'T;

EID: 0034332930     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(00)01492-X     Document Type: Review

References (49)

1. Defining epitopes: it's not as easy as it seems
2. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor
3. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis
4. Human growth hormone and extracellular domain of its receptor: crystal structure and of the complex
5. Binding in the growth hormone receptor complex
6. Haematopoietic receptor complexes
7. A hot spot of binding energy in a hormone-receptor interface
8. Crystal structure of the interleukin-4/receptor chain complex reveals a mosaic binding interface
9. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes
10. IL-6 type cytokine receptor complexes: hexamer or tetramer or both?
11. Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation
12. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells
13. Rational design of a mouse granulocyte macrophage-colony-stimulating factor receptor antagonist
14. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo
15. Small peptides as potent mimetics of the protein hormone erythropoietin
16. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A
17. Structural plasticity in a remodeled protein-protein interface
18. Convergent solutions to binding at a protein-protein interface
19. Minimized proteins
20. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice
21. Identification of a gp130 cytokine receptor critical site involved in oncostatin M response
22. Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants
23. Development of a human interleukin-6 receptor antagonist
24. Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding
25. Inter-species chimeras of leukaemia inhibitory factor define a major human receptor-binding determinant
26. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis
27. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction
28. Identification of single amino acid residues of human interleukin-6 involved in receptor binding and signal initiation
29. The unusual species cross-reactivity of the leukemia inhibitory factor receptor alpha-chain is determined primarily by the immunoglobulin-like domain
30. Receptor recognition sites of cytokines are organized as exchangeable modules: transfer of the LIFR binding site from CNTF to IL-6
31. Neuropoietic cytokines in the hematopoietic fold
32. Rational design of a GCN4-derived mimetic of interleukin-4
33. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6
34. Interleukin-6 and soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis
35. Sympathetic Neurons can produce and respond to Interleukin-6
36. Neuronal activities of IL-6 type cytokines often depend on soluble cytokine receptors
37. Novel path of activation of primary human smooth muscle cells: upregulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor
38. Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of the antiapoptotic resistance of lamina propria T cells
39. A designer cytokine with high activity on human hematopoietic progenitor cells
40. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130
41. A new type of Cytokine Receptor Antagonist directly targeting gp130
42. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells
43. Semirational design of a potent, artificial agonist of fibroblast growth factor receptors
44. Rapid evolution of a protein in vitro by DNA shuffling
45. DNA shuffling of a family of genes from diverse species accelerates directed evolution
46. Optimization of DNA shuffling for high fidelity recombination
47. Evolution of a cytokine using DNA family shuffling
48. A combinatorial approach to hybrid enzymes independent of DNA homology
49. Directed evolution of new catalytic activity using the alpha/beta-barrel scaffold